Revista de Biología Tropical ISSN Impreso: 0034-7744 ISSN electrónico: 2215-2075

Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer
Volumen 66 Número Regular Marzo 2018
HTML (Español (España))

Supplementary Files

Untitled (Español (España))


Gastric cancer
Helicobacter pylori
plasminogen activator system
Cáncer gástrico
Helicobacter pylori
sistema activador de plasminógeno

How to Cite

Alpízar-Alpízar, W., Malespín-Bendaña, W., Une, C., & Ramírez-Mayorga, V. (2017). Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer. Revista De Biología Tropical, 66(1), 28–47.


Gastric cancer is ranked as the third death-causing cancer and one of the most incident malignancies worldwide. Although Helicobacter pylori is the most well-established risk factor for the development of this neoplasm, most of the infected individuals do not develop gastric cancer. Two of the main challenges faced by the world’s scientific community in the combat against gastric cancer are the unraveling of its pathogenesis and the identification of novel ways to bring down the mortality. Malignant cell invasion of the non-neoplastic adjacent tissue and metastasis are pivotal events during cancer development and progression. Both processes are facilitated by proteases capable of degrading components of the extracellular matrix, some of which have been associated to clinico-pathological aspects of the disease. Recent studies have suggested the possible connection between H. pylori and the expression of some of these proteases in gastric mucosa. This review summarizes the current knowledge about epidemiological, clinical and biological aspects of gastric cancer; it also discusses the main findings about the involvement of the plasminogen activation system in the development and progression of this disease, as well as its potential repercussions in the clinical setting.
HTML (Español (España))


Almasi, C. E., Høyer-Hansen, G., Christensen, I. J., & Pappot, H. (2009). Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS, 117, 755-761.

Almasi, C. E., Brasso, K., Iversen, P., Pappot, H., Høyer-Hansen, G., Danø, K., & Christensen, I. J. (2011). Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate, 71, 899-907.

Alpízar-Alpízar, W., Pérez-Pérez, G. I., Une, C., Cuenca, P., & Sierra, R. (2005). Association of interleukin-1B and interleukin-1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica. Clinical and Experimental Medicine, 5, 169-176.

Alpízar-Alpízar, W., Nielsen, B. S., Sierra, R., Illemann, M., Ramírez, J. A., Arias, A., … Laerum O. D. (2010). Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. International Journal of Cancer, 126, 405-415.

Alpízar-Alpízar, W., Christensen, I. J., Santoni-Rugiu, E., Skarstein, A., Ovrebo, K., Illemann, M., & Laerum, O. D. (2012). Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma. International Journal of Cancer, 131, E329-336.

Alpízar-Alpízar, W., Skindersoe, M. E., Rasmussen, L., Kriegbaum, M. C., Christensen, I. J., Laerum, O. D., Ploug, M. (2013). Helicobacter pylori colonization drives urokinase receptor expression in murine gastric epithelium during early pathogenesis. Helicobacter, 18(Issue supplement S1), 85.

Andreasen, P. A., Georg, B., Lund, L. R., Riccio, A., & Stacey, S. N. (1990). Plasminogen activator inhibitors: hormonally regulated serpins. Molecular and Cellular Endocrinology, 68, 1-19.

Andreasen, P. A., Egelund, R., & Petersen, H. H. (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences, 57, 25-40.

Bacchiocchi, R., Rubini, C., Pierpaoli, E., Borghetti, G., Procacci, P., Nocini, P. F., … Fazioli F. (2008). Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer, 8, 220.

Backert, S., & Blaser, M. J. (2016). The Role of CagA in the Gastric Biology of Helicobacter pylori. Cancer Research, 76, 4028-4031.

Baek, M. K., Kim, M. H., Jang, H. J., Park, J. S., Chung, I. J., Shin, B. A., Ahn, B. W., & Jung, Y. D. (2008). EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells. Oncology Reports, 20, 1569-1575.

Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., … Noël, A. (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. The Journal of Cell Biology, 152, 777-784.

Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., … Wooster, R. (2004). The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. British Journal of Cancer, 91, 355-358.

Basso, D., Zambon, C. F., Letley, D. P., Stranges, A., Marchet, A., Rhead, J. L., … Atherton, J. C. (2008). Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology, 135, 91-99.

Behrendt, N., List, K., Andreasen, P. A., & Danø, K. (2003). The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. The Biochemical Journal, 371, 277-287.

Bertuccio, P., Chatenoud, L., Levi, F., Praud, D., Ferlay, J., Negri, E., … La Vecchia, C. (2009). Recent patterns in gastric cancer: a global overview. International Journal of Cancer, 125, 666-673.

Beyer, B. C., Heiss, M. M., Simon, E. H., Gruetzner, K. U., Babic, R., Jauch, K. W., … Allgayer, H. (2006). Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer, 106, 1026-1035.

Binder, B. R., & Mihaly, J. (2008). The plasminogen activator inhibitor "paradox" in cancer. Immunology Letters, 118, 116-124.

Blaser, M. J. (2008). Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prevention Research, 1, 308-311.

Blaser, M. J., Chen, Y., & Reibman, J. (2008). Does Helicobacter pylori protect against asthma and allergy? Gut, 57, 561-567.

Blasi, F., & Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nature Reviews Molecular Cell Biology, 3, 932-943.

Brenner, H., Arndt, V., Stürmer, T., Stegmaier, C., Ziegler, H., & Dhom, G. (2000). Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer, 88, 274-279.

Brenner, H., Rothenbacher, D., & Arndt, V. (2009). Epidemiology of stomach cancer. Methods in Molecular Biology, 472, 467-477.

Brungs, D., Chen, J., Aghmesheh, M., Vine, K. L., Becker, T. M., Carolan, M. G., & Ranson, M. (2017). The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis. Oncotarget, 8, 23099-23109.

Bugge, T. H., Lund, L. R., Kombrinck, K. K., Nielsen, B. S., Holmbäck, K., Drew, A. F., … Degen, J. L. (1998). Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene, 16, 3097-3104.

Carneiro, F. (2012). Hereditary gastric cancer. Pathologe, 33(Suppl 2), 231-234.

Carneiro, F., Oliveira, C., Suriano, G., & Seruca, R. (2008). Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. Journal of Clinical Pathology, 61, 25-30.

Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2005). Gastric cancer. Critical Reviews in Oncology/Hematology, 54, 209-241.

Chaurasia, P., Aguirre-Ghiso, J. A., Liang, O. D., Gardsvoll, H., Ploug, M., & Ossowski, L. (2006). A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. The Journal of Biological Chemistry, 281, 14852-14863.

Chen, Y., & Blaser, M. J. (2008). Helicobacter pylori colonization is inversely associated with childhood asthma. The Journal of Infectious Diseases, 198, 553-560.

Colquhoun, A., Arnold, M., Ferlay, J., Goodman, K. J., Forman, D., & Soerjomataram, I. (2015). Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut, 64, 1881-1888.

Correa, P. (1992). Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Research, 52, 6735-6740.

Correa, P. (2004). The biological model of gastric carcinogenesis. IARC Scientific Publications, 301-310.

Correa, P., & Houghton, J. (2007). Carcinogenesis of Helicobacter pylori. Gastroenterology, 133, 659-672.

Correa, P., Piazuelo, M. B., & Wilson, K. T. (2010). Pathology of gastric intestinal metaplasia: clinical implications. American Journal of Gastroenterology, 105, 493-498.

Cover, T. L. (2016). Helicobacter pylori Diversity and Gastric Cancer Risk. MBio, 7, e01869-01815. doi: 10.1128/mBio.01869-15

Cover, T. L., & Blanke, S. R. (2005). Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nature Reviews Microbiology, 3, 320-332.

Czekay, R. P., Aertgeerts, K., Curriden, S. A., & Loskutoff, D. J. (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. The Journal of Cell Biology, 160, 781-791.

Danø, K., Rømer, J., Nielsen, B. S., Bjørn, S., Pyke, C., Rygaard, J., & Lund, L. R. (1999). Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. APMIS, 107, 120-127.

Danø, K., Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., & Rømer, J. (2005). Plasminogen activation and cancer. Thrombosis and Haemostasis, 93, 676-681.

Derakhshan, M. H., Malekzadeh, R., Watabe, H., Yazdanbod, A., Fyfe, V., Kazemi, A., … McColl, K. E. (2008). Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut, 57, 298-305.

Dicken, B. J., Bigam, D. L., Cass, C., Mackey, J. R., Joy, A. A., & Hamilton, S. M. (2005). Gastric adenocarcinoma: review and considerations for future directions. Annals of Surgery, 241, 27-39.

Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., & Andreasen, P. (1990). Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Research, 50, 6827-6829.

Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2, 161-174.

El-Etr, S. H., Mueller, A., Tompkins, L. S., Falkow, S., & Merrell, D. S. (2004). Phosphorylation-independent effects of CagA during interaction between Helicobacter pylori and T84 polarized monolayers. The Journal of Infectious Diseases, 190, 1516-1523.

El-Omar, E. M., Carrington, M., Chow, W. H., McColl, K. E., Bream, J. H., Young, H. A., … & Rabkin, C. S. (2000a). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404, 398-402.

El-Omar, E. M., Oien, K., Murray, L. S., El-Nujumi, A., Wirz, A., Gillen, D., … McColl, K. E. (2000b). Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology, 118, 22-30.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., … Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-386.

Fock, K. M., Talley, N., Moayyedi, P., Hunt, R., Azuma, T., Sugano, K., Asia-Pacific gastric Cancer Consensus Conference. (2008). Asia-Pacific consensus guidelines on gastric cancer prevention. Journal of Gastroenterology and Hepatology, 23, 351-365.

Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., … Klijn, J. G. (2000). The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Research, 60, 636-643.

Forman, D., & Burley, V. J. (2006). Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Practice & Research Clinical Gastroenterology, 20, 633-649.

Fox, J. G., & Wang, T. C. (2007). Inflammation, atrophy, and gastric cancer. The Journal of Clinical Investigation, 117, 60-69.

Goldenring, J. R., Nam, K. T., & Mills, J. C. (2011). The origin of pre-neoplastic metaplasia in the stomach: chief cells emerge from the Mist. Experimental Cell Research, 317, 2759-2764.

Grøndahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brünner, N., Mouridsen, H. T., Danø, K., & Blichert-Toft, M. (1993). High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Research, 53, 2513-2521.

Grøndahl-Hansen, J., Peters, H. A., van Putten, W. L., Look, M. P., Pappot, H., Rønne, E., … Foekens, J. A. (1995). Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clinical Cancer Research, 1, 1079-1087.

Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., … Reeve, A. E. (1998). E-cadherin germline mutations in familial gastric cancer. Nature, 392, 402-405.

Guillemin, K., Salama, N. R., Tompkins, L. S., & Falkow, S. (2002). Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection. Proceedings of the National Academy of Sciences of the United States of America, 99, 15136-15141.

Guo, H., Ling, C., Ma, Y. Y., Zhou, L. X., & Zhao, L. (2015). Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis. OncoTargets and Therapy, 8, 1503-1509.

Gårdsvoll, H., & Ploug, M. (2007). Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. The Journal of Biological Chemistry, 282, 13561-13572.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-674.

Hansen, S., Vollset, S. E., Derakhshan, M. H., Fyfe, V., Melby, K. K., Aase, S., … McColl, K. E. (2007). Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut, 56, 918-925.

Hansford, S., Kaurah, P., Li-Chang, H., Woo, M., Senz, J., Pinheiro, H., … Huntsman D. G. (2015). Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncology, 1, 23-32.

Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., … Oncology, A. S. O. C. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25, 5287-5312.

Hatakeyama, M. (2014). Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe, 15, 306-316.

Hayakawa, Y., Sethi, N., Sepulveda, A. R., Bass, A. J., & Wang, T. C. (2016). Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nature Reviews Cancer, 16, 305-318.

Heiss, M. M., Allgayer, H., Gruetzner, K. U., Funke, I., Babic, R., Jauch, K. W., & Schildberg, F. W. (1995a). Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Medicine, 1, 1035-1039.

Heiss, M. M., Babic, R., Allgayer, H., Gruetzner, K. U., Jauch, K. W., Loehrs, U., & Schildberg, F. W. (1995b). Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. Journal of Clinical Oncology, 13, 2084-2093.

Heiss, M. M., Simon, E. H., Beyer, B. C., Gruetzner, K. U., Tarabichi, A., Babic, R., … Allgayer, H. (2002). Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. Journal of Clinical Oncology, 20, 2005-2016.

Henic, E., Borgfeldt, C., Christensen, I. J., Casslén, B., & Høyer-Hansen, G. (2008). Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clinical Cancer Research, 14, 5785-5793.

Huang, Q., Sun, Q., Fang, X. S., Zhou, D., & Zou, X. P. (2016). Recent advances in proximal gastric carcinoma. Journal of Digestive Diseases, 17, 421-432.

Huntsman, D. G., Carneiro, F., Lewis, F. R., MacLeod, P. M., Hayashi, A., Monaghan, K. G., … Caldas, C. (2001). Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. New England Journal of Medicine, 344, 1904-1909.

Høyer-Hansen, G., & Lund, I. K. (2007). Urokinase receptor variants in tissue and body fluids. Advances in Clinical Chemistry, 44, 65-102.

Illemann, M., Bird, N., Majeed, A., Laerum, O. D., Lund, L. R., Danø, K., & Nielsen, B. S. (2009). Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. International Journal of Cancer, 124, 1860-1870.

Imamura, S., Sugimoto, M., Kanemasa, K., Sumida, Y., Okanoue, T., Yoshikawa, T., & Yamaoka, Y. (2010). Inverse association between Helicobacter pylori infection and allergic rhinitis in young Japanese. Journal of Gastroenterology and Hepatology, 25, 1244-1249.

Iwamoto, J., Takahashi, K., Mizokami, Y., Otsubo, T., Miura, S., Narasaka, T., … Matsuoka, T. (2003). Expression of urokinase-type plasminogen activator and its receptor in gastric fibroblasts and effects of nonsteroidal antiinflammatory drugs and prostaglandin. Digestive Diseases and Sciences, 48, 2247-2256.

Iwamoto, J., Mizokami, Y., Takahashi, K., Nakajima, K., Ohtsubo, T., Miura, S., … Matsuoka, T. (2005). Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Scandinavian Journal of Gastroenterology, 40, 783-793.

Iwamoto, J., Mizokami, Y., Takahashi, K., Matsuoka, T., & Matsuzaki, Y. (2008). The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells. Helicobacter, 13, 174-182.

Japanese Gastric Cancer, A. (1998). Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer, 1, 10-24.

Jänicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., … German N0 Study Group. (2001). Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of the National Cancer Institute, 93, 913-920.

Kamangar, F., Dores, G. M., & Anderson, W. F. (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology, 24, 2137-2150.

Kaneko, T., Konno, H., Baba, M., Tanaka, T., & Nakamura, S. (2003). Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Science, 94, 43-49.

Kawasaki, K., Hayashi, Y., Wang, Y., Suzuki, S., Morita, Y., Nakamura, T., … Kuroda, Y. (1998). Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer. Journal of Gastroenterology and Hepatology, 13, 936-944.

Kenny, S., Duval, C., Sammut, S. J., Steele, I., Pritchard, D. M., Atherton, J. C., … Varro, A. (2008). Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. American Journal of Physiology Gastrointestinal and Liver Physiology, 295, G431-441.

Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67.

Kim, M. H., Yoo, H. S., Chang, H. J., Hong, M. H., Kim, H. D., Chung, I. J., … Jung, Y. D. (2005). Urokinase plasminogen activator receptor is upregulated by Helicobacter pylori in human gastric cancer AGS cells via ERK, JNK, and AP-1. Biochemical and Biophysical Research Communications, 333, 874-880.

Kim, M. H., Park, J. S., Chang, H. J., Baek, M. K., Kim, H. R., Shin, B. A., … Jung, Y. D. (2008). Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells. Journal of Cellular Biochemistry, 104, 1102-1112.

Kim, M. H., Yoo, H. S., Kim, M. Y., Jang, H. J., Baek, M. K., Kim, H. R., … Jung, Y. D. (2007). Helicobacter pylori stimulates urokinase plasminogen activator receptor expression and cell invasiveness through reactive oxygen species and NF-kappaB signaling in human gastric carcinoma cells. International Journal of Molecular Medicine, 19, 689-697.

Kita, Y., Fukagawa, T., Mimori, K., Kosaka, Y., Ishikawa, K., Aikou, T., … Mori, M. (2009). Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. British Journal of Cancer, 100, 153-159.

Kodaman, N., Pazos, A., Schneider, B. G., Piazuelo, M. B., Mera, R., Sobota, R. S., … Correa P. (2014). Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proceedings of the National Academy of Sciences of the United States of America, 111, 1455-1460.

Kokkola, A., Kosunen, T. U., Puolakkainen, P., Sipponen, P., Harkonen, M., Laxen, F., … Rautelin, H. (2003). Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS, 111, 619-624.

Kriegbaum, M. C., Persson, M., Haldager, L., Alpízar-Alpízar, W., Jacobsen, B., Gårdsvoll, H., … Ploug, M. (2011). Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Current Drug Targets, 12, 1711-1728.

Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., … Semenza, G. L. (2003). Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Research, 63, 1138-1143.

Kristensen, P., Larsson, L. I., Nielsen, L. S., Grøndahl-Hansen, J., Andreasen, P. A., & Danø, K. (1984). Human endothelial cells contain one type of plasminogen activator. FEBS Letters, 168, 33-37.

Kyburz, A., & Müller, A. (2017). Helicobacter pylori and Extragastric Diseases. Current Topics in Microbiology and Immunology, 400, 325-347.

Laerum, O. D., Ovrebo, K., Skarstein, A., Christensen, I. J., Alpízar-Alpízar, W., Helgeland, L., … Illemann, M. (2012). Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. International Journal of Cancer, 131, 558-569.

Lamarre, J., Vasudevan, J., & Gonias, S. L. (1994). Plasmin cleaves betaglycan and releases a 60 kDa transforming growth factor-beta complex from the cell surface. The Biochemical Journal, 302( Pt 1), 199-205.

Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017). Emerging Biological Principles of Metastasis. Cell, 168, 670-691.

Larsson, S. C., Bergkvist, L., & Wolk, A. (2006a). Fruit and vegetable consumption and incidence of gastric cancer: a prospective study. Cancer Epidemiology Biomarkers & Prevention, 15, 1998-2001.

Larsson, S. C., Orsini, N., & Wolk, A. (2006b). Processed meat consumption and stomach cancer risk: a meta-analysis. Journal of the National Cancer Institute, 98, 1078-1087.

Lauren, P. (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histological clasification. Acta Pathologica et Microbiologica Scandinavica, 64, 31-49.

Lee, D. H., Yang, Y., Lee, S. J., Kim, K. Y., Koo, T. H., Shin, S. M., … Lee, J. H. (2003). Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Research, 63, 4648-4655.

Lee, K. H., Bae, S. H., Lee, J. L., Hyun, M. S., Kim, S. H., Song, S. K., & Kim, H. S. (2004). Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology, 66, 210-217.

Lee, K. H., Choi, E. Y., Kim, M. K., Hyun, M. S., Jang, B. I., Kim, T. N., … Kim, J. R. (2006). Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines. Experimental & Molecular Medicine, 38, 27-35.

Lengyel, E., Gum, R., Stepp, E., Juárez, J., Wang, H., & Boyd, D. (1996a). Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. Journal of Cellular Biochemistry, 61, 430-443.

Lengyel, E., Wang, H., Stepp, E., Juárez, J., Wang, Y., Doe, W., … Boyd, D. (1996b). Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. The Journal of Biological Chemistry, 271, 23176-23184.

Lijnen, H. R. (2002). Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Moscow), 67, 92-98.

Lindberg, P., Larsson, A., & Nielsen, B. S. (2006). Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. International Journal of Cancer, 118, 2948-2956.

Liotta, L. A., Goldfarb, R. H., Brundage, R., Siegal, G. P., Terranova, V., & Garbisa, S. (1981). Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Research, 41, 4629-4636.

Liu, C., & Russell, R. M. (2008). Nutrition and gastric cancer risk: an update. Nutrition Reviews, 66, 237-249.

Liu, D., Aguirre-Ghiso, J., Estrada, Y., & Ossowski, L. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell, 1, 445-457.

Look, M. P., van Putten, W. L., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., … Foekens, J. A. (2002). Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Journal of the National Cancer Institute, 94, 116-128.

Lund, I. K., Illemann, M., Thurison, T., Christensen, I. J., & Høyer-Hansen, G. (2011). uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Current Drug Targets, 12, 1744-1760.

Lynch, H. T., Grady, W., Suriano, G., & Huntsman, D. (2005). Gastric cancer: new genetic developments. Journal of Surgical Oncology, 90, 114-133.

Madsen, C. D., & Sidenius, N. (2008). The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. European Journal of Cell Biology, 87, 617-629.

Maurer, G. D., Leupold, J. H., Schewe, D. M., Biller, T., Kates, R. E., Hornung, H. M., … Allgayer, H. (2007). Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clinical Cancer Research, 13, 1123-1132.

McColl, K. E. (2006). Cancer of the gastric cardia. Best Practice & Research Clinical Gastroenterology, 20, 687-696.

Migita, T., Sato, E., Saito, K., Mizoi, T., Shiiba, K., Matsuno, S., … Ohtani, H. (1999). Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. International Journal of Cancer, 84, 74-79.

Müller, A., Oertli, M., & Arnold, I. C. (2011). H. pylori exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection. Cell Communication and Signaling, 9, 25.

Nagar, B., Overduin, M., Ikura, M., & Rini, J. M. (1996). Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature, 380, 360-364.

Naumann, M., Sokolova, O., Tegtmeyer, N., & Backert, S. (2017). Helicobacter pylori: A Paradigm Pathogen for Subverting Host Cell Signal Transmission. Trends in Microbiology, 25, 316-328.

Nobili, S., Bruno, L., Landini, I., Napoli, C., Bechi, P., Tonelli, F., … Nesi, G. (2011). Genomic and genetic alterations influence the progression of gastric cancer. World Journal of Gastroenterology, 17, 290-299.

Odenbreit, S., Puls, J., Sedlmaier, B., Gerland, E., Fischer, W., & Haas, R. (2000). Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science, 287, 1497-1500.

Ohnishi, N., Yuasa, H., Tanaka, S., Sawa, H., Miura, M., Matsui, A., … Hatakeyama, M. (2008). Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proceedings of the National Academy of Sciences of the United States of America, 105, 1003-1008.

Oliveira, C., Seruca, R., & Carneiro, F. (2006). Genetics, pathology, and clinics of familial gastric cancer. International Journal of Surgical Pathology, 14, 21-33.

Ossowski, L., Russo-Payne, H., & Wilson, E. L. (1991). Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Research, 51, 274-281.

Park, J. S., Park, J. H., Khoi, P. N., Joo, Y. E., & Jung, Y. D. (2011). MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-kappaB signals in gastric cancer cells. Carcinogenesis, 32, 175-181.

Parkin, D. M. (2001). Global cancer statistics in the year 2000. Lancet Oncology, 2, 533-543.

Parkin, D. M. (2006). The global health burden of infection-associated cancers in the year 2002. International Journal of Cancer, 118, 3030-3044.

Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians, 55, 74-108.

Pedersen, H., Brünner, N., Francis, D., Osterlind, K., Rønne, E., Hansen, H. H., … Grøndahl-Hansen, J. (1994a). Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Research, 54, 4671-4675.

Pedersen, H., Grøndahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Danø, K., & Brünner, N. (1994b). Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Research, 54, 120-123.

Peek, R. M., Fiske, C., & Wilson, K. T. (2010). Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiological Reviews, 90, 831-858.

Petrovchich, I., & Ford, J. M. (2016). Genetic predisposition to gastric cancer. Seminars in Oncology, 43, 554-559.

Piironen, T., Haese, A., Huland, H., Steuber, T., Christensen, I. J., Brünner, N., … Lilja, H. (2006). Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clinical Chemistry, 52, 838-844.

Plesner, T., Ploug, M., Ellis, V., Rønne, E., Høyer-Hansen, G., Wittrup, M., Pedersen, T. L., … Hansen, N. E. (1994a). The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood, 83, 808-815.

Plesner, T., Ralfkiaer, E., Wittrup, M., Johnsen, H., Pyke, C., Pedersen, T. L., … Danø, K. (1994b). Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. American Journal of Clinical Pathology, 102, 835-841.

Ploug, M. (2003). Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Current Pharmaceutical Design, 9, 1499-1528.

Polk, D. B., & Peek, R. M. Jr. (2010). Helicobacter pylori: gastric cancer and beyond. Nature Reviews Cancer, 10, 403-414.

Pyke, C., Salo, S., Ralfkiaer, E., Rømer, J., Danø, K., & Tryggvason, K. (1995). Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Research, 55, 4132-4139.

Redaniel, M. T., Laudico, A., Mirasol-Lumague, M. R., Gondos, A., Pulte, D., Mapua, C., & Brenner, H. (2009). Cancer survival discrepancies in developed and developing countries: comparisons between the Philippines and the United States. British Journal of Cancer, 100, 858-862.

Rhead, J. L., Letley, D. P., Mohammadi, M., Hussein, N., Mohagheghi, M. A., Eshagh Hosseini, M., & Atherton, J. C. (2007). A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology, 133, 926-936.

Rieke, C., Papendieck, A., Sokolova, O., & Naumann, M. (2011). Helicobacter pylori-induced tyrosine phosphorylation of IKKβ contributes to NF-κB activation. Biological Chemistry, 392, 387-393.

Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., … Karin, M. (2008). NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 453, 807-811.

Salama, N. R., Hartung, M. L., & Müller, A. (2013). Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nature Reviews Microbiology, 11, 385-399.

Schewe, D. M., Leupold, J. H., Boyd, D. D., Lengyel, E. R., Wang, H., Gruetzner, K. U., … Allgayer, H. (2003). Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clinical Cancer Research, 9, 2267-2276.

Schewe, D. M., Biller, T., Maurer, G., Asangani, I. A., Leupold, J. H., Lengyel, E. R., … Allgayer, H. (2005). Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clinical Cancer Research, 11, 8538-8548.

Sepulveda, A. R., Tao, H., Carloni, E., Sepulveda, J., Graham, D. Y., & Peterson, L. E. (2002). Screening of gene expression profiles in gastric epithelial cells induced by Helicobacter pylori using microarray analysis. Alimentary Pharmacology & Therapeutics, 16(Suppl 2), 145-157.

Shaffer, C. L., Gaddy, J. A., Loh, J. T., Johnson, E. M., Hill, S., Hennig, E. E., … Cover, T. L. (2011). Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface. PLoS Pathogens, 7, e1002237.

Sierra, M. S., Cueva, P., Bravo, L. E., & Forman, D. (2016). Stomach cancer burden in Central and South America. Cancer Epidemiology, 44(Suppl 1), S62-S73.

Sieuwerts, A. M., Martens, J. W., Dorssers, L. C., Klijn, J. G., & Foekens, J. A. (2002). Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts. Thrombosis and Haemostasis, 87, 674-683.

Smith, H. W., & Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nature Reviews Mollecular Cell Biology, 11, 23-36.

Sokolova, O., Maubach, G., & Naumann, M. (2014). MEKK3 and TAK1 synergize to activate IKK complex in Helicobacter pylori infection. Biochimica et Biophysica Acta, 1843, 715-724.

Stephens, R. W., Nielsen, H. J., Christensen, I. J., Thorlacius-Ussing, O., Sørensen, S., Danø, K., & Brünner, N. (1999). Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. Journal of the Nationall Cancer Institute, 91, 869-874.

Suerbaum, S., & Michetti, P. (2002). Helicobacter pylori infection. New England Journal of Medicine, 347, 1175-1186.

Suh, Y. S., Lee, H. J., Jung, E. J., Kim, M. A., Nam, K. T., Goldenring, J. R., … Kim, W. H. (2012). The combined expression of metaplasia biomarkers predicts the prognosis of gastric cancer. Annals of Surgical Oncology, 19, 1240-1249.

Tan, S., Tompkins, L. S., & Amieva, M. R. (2009). Helicobacter pylori usurps cell polarity to turn the cell surface into a replicative niche. PLoS Pathogens, 5, e1000407.

Tramacere, I., Negri, E., Pelucchi, C., Bagnardi, V., Rota, M., Scotti, L., … Boffetta, P. (2012). A meta-analysis on alcohol drinking and gastric cancer risk. Annals of Oncology, 23, 28-36.

Tricker, A. R., & Preussmann, R. (1991). Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutation Research, 259, 277-289.

Tsugane, S., & Sasazuki, S. (2007). Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer, 10, 75-83.

Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., … Schlemper, R. J. (2001). Helicobacter pylori infection and the development of gastric cancer. New England Journal of Medicine, 345, 784-789.

Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147, 275-292.

Valle, J., Kekki, M., Sipponen, P., Ihamaki, T., & Siurala, M. (1996). Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scandinavian Journal of Gastroenterology, 31, 546-550.

Wang, Y., Dang, J., Wang, H., Allgayer, H., Murrell, G. A., & Boyd, D. (2000). Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. European Journal of Biochemistry, 267, 3248-3254.

Wang G., Hu, N., Yang, H. H., Wang, L., Su, H., Wang, C., … Lee, M. P. (2013). Comparison of global gene expression of gastric cardia and noncardia cancers from a high-risk population of China. PLoS One, 8, e63826.

Wroblewski, L. E., Peek, R. M. Jr., & Wilson, K. T. (2010). Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clinical Microbiology Reviews, 23, 713-739.

Yakirevich, E., & Resnick, M. B. (2013). Pathology of gastric cancer and its precursor lesions. Gastroenterology Clinics of North America, 42, 261-284.

Yamaoka, Y. (2010). Mechanisms of disease: Helicobacter pylori virulence factors. Nature Reviews Gastroenterology & Hepatology, 7, 629-641.

Yasui, W., Sentani, K., Sakamoto, N., Anami, K., Naito, Y., & Oue, N. (2011). Molecular pathology of gastric cancer: research and practice. Pathology Research and Practice, 207, 608-612.

Yoshida, E., Tsuchiya, K., Sugiki, M., Sumi, H., Mihara, H., & Maruyama, M. (1996). Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation, 20, 319-326.

Yu, W., Kim, J., & Ossowski, L. (1997). Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. The Journal of Cell Biology, 137, 767-777.

Yuasa, Y. (2003). Control of gut differentiation and intestinal-type gastric carcinogenesis. Nature Reviews Cancer, 3, 592-600.

Zhang, L., Zhao, Z. S., Ru, G. Q., & Ma, J. (2006). Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World Journal of Gastroenterology, 12, 3970-3976.

Zhao, W., Wang, X., Qu, B., Huang, X., & Wang, H. (2002). Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients. Chinese Medical Journal, 115, 702-704.



Download data is not yet available.